<code id='EA18112ECC'></code><style id='EA18112ECC'></style>
    • <acronym id='EA18112ECC'></acronym>
      <center id='EA18112ECC'><center id='EA18112ECC'><tfoot id='EA18112ECC'></tfoot></center><abbr id='EA18112ECC'><dir id='EA18112ECC'><tfoot id='EA18112ECC'></tfoot><noframes id='EA18112ECC'>

    • <optgroup id='EA18112ECC'><strike id='EA18112ECC'><sup id='EA18112ECC'></sup></strike><code id='EA18112ECC'></code></optgroup>
        1. <b id='EA18112ECC'><label id='EA18112ECC'><select id='EA18112ECC'><dt id='EA18112ECC'><span id='EA18112ECC'></span></dt></select></label></b><u id='EA18112ECC'></u>
          <i id='EA18112ECC'><strike id='EA18112ECC'><tt id='EA18112ECC'><pre id='EA18112ECC'></pre></tt></strike></i>

          fashion

          fashion

          author:entertainment    Page View:4
          Matts Take Column Illustration
          Molly Ferguson for STAT

          If you’re a drug company executive, you probably feel like you got up on the wrong side of bed.

          On Thursday night, President Biden proposed expanding one of his most popular policies: the Medicare price negotiation process that was put in place as part of the Inflation Reduction Act. “Americans pay more for prescription drugs than anywhere else,” Biden said. “It’s wrong and I’m ending it.”

          advertisement

          Obviously, the drug industry is not going to be happy about new price limitations in the U.S., the biggest market for pharmaceuticals. But, even more than that, Biden’s move emphasizes a painful reality: That pharmaceutical companies remain one of the biggest political targets in the country — despite their key role in addressing the Covid-19 pandemic and their development of wildly effective new weight loss drugs.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          comprehensive

          Drug repurposing or repositioning? The language matters
          Drug repurposing or repositioning? The language matters

          AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

          read more
          Eli Lilly to acquire DICE Therapeutics in $2.4 billion deal
          Eli Lilly to acquire DICE Therapeutics in $2.4 billion deal

          DarronCummings/APEliLillysaidTuesdaythatitwillpurchaseDICETherapeutics,asmallcompanydevelopinganexpe

          read more
          BioMarin wins approval for gene therapy to treat hemophilia A
          BioMarin wins approval for gene therapy to treat hemophilia A

          AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

          read more

          Russians and Belarusians back at Wimbledon as war in Ukraine continues

          VictoriaAzarenkaofBelarusplaysareturntoChina'sYuanYueduringthefirstroundwomen'ssinglesmatchondayoneo